Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus endocrine therapy in HR+ early breast cancer (real-world, adjuvant)
ChiCTR2200057215Phase 4Not yet recruiting
- Sponsor
- The First People's Hospital of Yunnan Province
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by The First People's Hospital of Yunnan Province. Primary endpoint: Invasive disease-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200057215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057215.